Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB

Introduction: Drug targeting to brain by circumventing the physiological barriers is a prerequisite for drugs acting on central nervous system (CNS) and therapeutic potential of many drugs can be improved by effectively targeting the drug(s) to brain. Areas covered: Present review describes blood–brain barrier (BBB), drug transport mechanisms and factors affecting drug transportation across BBB along with in vitro BBB models; and the approaches for evaluation of permeability of drug across BBB. Expert opinion: The development of a still awaited perfect in vitro model to mimic BBB is a challenging task. System biologist, network biologist and computational technologist should come together to integrate the role of transporters, physiological and pathophysiological complexity of BBB to replicate vascular properties of the brain microcapillaries as a suitable model to facilitate the high-throughput screening of CNS acting biomolecules.

[1]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[2]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[3]  C F Dewey,et al.  Apparatus for subjecting living cells to fluid shear stress. , 1982, The Review of scientific instruments.

[4]  W. Pardridge,et al.  Blood—Brain Barrier Genomics , 2001, Methods in molecular medicine.

[5]  W. Hennink,et al.  In Vivo Methods to Study Uptake of Nanoparticles into the Brain , 2010, Pharmaceutical Research.

[6]  R. Yokel,et al.  Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses , 2010, Journal of drug targeting.

[7]  N. Greig,et al.  Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain , 2004, Cancer Chemotherapy and Pharmacology.

[8]  Bhavna,et al.  Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor , 2007 .

[9]  M. Nair,et al.  Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier , 2010, International journal of nanomedicine.

[10]  W. Pardridge Blood-Brain Barrier Genomics , 2007, Stroke.

[11]  R. Sharma,et al.  Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[12]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[13]  L. Fenart,et al.  Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  Senshang Lin,et al.  Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. , 2005, Journal of pharmaceutical sciences.

[15]  Ming Lei,et al.  Hard and soft micromachining for BioMEMS: review of techniques and examples of applications in microfluidics and drug delivery. , 2004, Advanced drug delivery reviews.

[16]  Yan Zhang,et al.  Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  R. Löbenberg,et al.  Influence of the surfactant concentration on the body distribution of nanoparticles. , 1999, Journal of drug targeting.

[18]  A. Seelig The use of monolayers for simple and quantitative analysis of lipid-drug interactions exemplified with dibucaine and substance P. , 1990, Cell biology international reports.

[19]  M. Heimesaat,et al.  SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers , 2011, Journal of drug targeting.

[20]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[21]  R. Cavalli,et al.  Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. , 2000, Pharmacological research.

[22]  Xin-guo Jiang,et al.  UEA I-bearing nanoparticles for brain delivery following intranasal administration. , 2007, International journal of pharmaceutics.

[23]  J. Gee,et al.  Astrocytes: regulation of brain homeostasis via apolipoprotein E. , 2005, The international journal of biochemistry & cell biology.

[24]  S. Davis,et al.  Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits , 1986 .

[25]  R. Alyautdin,et al.  Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles , 1997 .

[26]  B. Sabel,et al.  Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood–Brain Barrier , 1998, Peptides.

[27]  Rongqin Huang,et al.  Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo , 2010, Brain Research Bulletin.

[28]  Nicholas A Peppas,et al.  Molecular imprinting within hydrogels. , 2002, Advanced drug delivery reviews.

[29]  Zhuang Liu,et al.  Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. , 2006, Angewandte Chemie.

[30]  E. Souto,et al.  Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. , 2012, International journal of pharmaceutics.

[31]  D. Gopinath,et al.  1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice , 2007, Journal of drug targeting.

[32]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  L. Fenart,et al.  A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier , 1997, The Journal of cell biology.

[34]  L. Ren,et al.  Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles , 2011, International journal of nanomedicine.

[35]  K. Landfester,et al.  The First Step into the Brain: Uptake of NIO‐PBCA Nanoparticles by Endothelial Cells in vitro and in vivo, and Direct Evidence for their Blood–Brain Barrier Permeation , 2008, ChemMedChem.

[36]  H. Boriss Brain Availability Is the Key Parameter for Optimising the Permeability of Central Nervous System Drugs , 2010 .

[37]  B. Sabel,et al.  Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. , 2000, Life sciences.

[38]  Alexander V Kabanov,et al.  Nanogels for oligonucleotide delivery to the brain. , 2004, Bioconjugate chemistry.

[39]  D. A. Kharkevich,et al.  [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles]. , 1996, Eksperimental'naia i klinicheskaia farmakologiia.

[40]  A. Babbar,et al.  Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. , 2008, International journal of pharmaceutics.

[41]  郑俊海,et al.  International Journal of Nanomedicine , 2022 .

[42]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[43]  L. Illum Is nose‐to‐brain transport of drugs in man a reality? , 2004, The Journal of pharmacy and pharmacology.

[44]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[45]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[46]  Xun Sun,et al.  Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[47]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[48]  R. Müller,et al.  Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate , 2002, Journal of drug targeting.

[49]  S. Usami,et al.  Molecular mechanism of endothelial growth arrest by laminar shear stress. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.

[51]  W. Surewicz,et al.  Interaction of propranolol with model phospholipid membranes. Monolayer, spin label and fluorescent spectroscopy studies. , 1981, Biochimica et biophysica acta.

[52]  S. Baboota,et al.  Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. , 2012, Carbohydrate polymers.

[53]  Meindert Danhof,et al.  Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier , 1997, Brain Research Reviews.

[54]  J. Brillault,et al.  Prediction of Drug Transport Through the Blood-Brain Barrier in Vivo: A Comparison Between Two in Vitro Cell Models , 2002, Pharmaceutical Research.

[55]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Tushar K. Vyas,et al.  Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. , 2008, International journal of pharmaceutics.

[57]  Edward J. Rapp,et al.  Side by side comparison between dynamic versus static models of blood–brain barrier in vitro: A permeability study , 2006, Brain Research.

[58]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[59]  X. Wu,et al.  Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.

[60]  T. Nagai,et al.  Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[61]  T. Paunesku,et al.  Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[62]  P. Diwan,et al.  Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[63]  C. Lohmann,et al.  Predicting Blood-Brain Barrier Permeability of Drugs: Evaluation of Different In Vitro Assays , 2002, Journal of drug targeting.

[64]  R. Müller,et al.  The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis , 2009, Journal of drug targeting.

[65]  C. Ropert,et al.  Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. , 1992, Biomaterials.

[66]  K. Audus,et al.  Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers , 1994 .

[67]  Javed Ali,et al.  Strategy for effective brain drug delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[68]  Murali Mohan Bommana,et al.  The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye , 2010, Nanotechnology.

[69]  Sandip S Chavhan,et al.  Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[70]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[71]  J. Rao,et al.  Fluorescence imaging in vivo: recent advances. , 2007, Current opinion in biotechnology.

[72]  E. Neuwelt,et al.  An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.

[73]  P. Gaillard,et al.  Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[74]  R. Borchardt,et al.  Carrier-mediated transport of the antitumor agent acivicin across the blood-brain barrier. , 1995, Biochemical pharmacology.

[75]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[76]  D. Begley,et al.  Polysorbate‐80 coating enhances uptake of polybutylcyanoacrylate (PBCA)‐nanoparticles by human and bovine primary brain capillary endothelial cells , 2000, The European journal of neuroscience.

[77]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[78]  M. Nireekshan Kumar,et al.  Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[79]  W. Pardridge,et al.  Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. , 1979, The Journal of clinical investigation.

[80]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[81]  B. Kapoor,et al.  P-glycoprotein: pharmacological relevance , 2006 .

[82]  T. Kundu,et al.  Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. , 2008, Nano letters.

[83]  D. Welty,et al.  Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate , 1993, Epilepsy Research.

[84]  Wei Lu,et al.  Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. , 2006, Biomaterials.

[85]  M A Vandelli,et al.  Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[86]  Y. Kuo,et al.  Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. , 2007, International journal of pharmaceutics.

[87]  Luca Cucullo,et al.  In vitro blood-brain barrier models: current and perspective technologies. , 2012, Journal of pharmaceutical sciences.

[88]  S. Rapoport,et al.  Tight‐Junctional Modification as the Basis of Osmotic Opening of the Blood‐Brain Barrier a , 1986, Annals of the New York Academy of Sciences.

[89]  Chen Jiang,et al.  Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.

[90]  Jijin Gu,et al.  The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. , 2012, Biomaterials.

[91]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[92]  J. Kreuter,et al.  Use of nanoparticles for cerebral cancer. , 2008, Tumori.

[93]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[94]  J. Kreuter,et al.  Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants , 1990 .

[95]  W H Oldendorf,et al.  Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. , 1970, Brain research.

[96]  J. Kaufman,et al.  Permeability of the blood‐brain barrier for atenolol studied by positron emission tomography , 1991, The Journal of pharmacy and pharmacology.

[97]  A. Dalpiaz,et al.  Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.

[98]  Jie Pan,et al.  Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. , 2008, Biomaterials.

[99]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[100]  S. Montoto,et al.  Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. , 2008, Blood.

[101]  Thomas Wisniewski,et al.  Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging , 2008, Journal of neuroscience research.

[102]  J. Frangioni In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.

[103]  W. Pardridge,et al.  Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.

[104]  M. Samanta,et al.  Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease , 2008, Brain Research.

[105]  M. R. Kumar,et al.  Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Xin-guo Jiang,et al.  Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles , 2009, Journal of drug targeting.

[107]  Anders Tunek,et al.  High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.

[108]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[109]  H. Gendelman,et al.  Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS1 , 2009, The Journal of Immunology.

[110]  Rakesh K. Sharma,et al.  Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels , 2006, Journal of drug targeting.

[111]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[112]  H. Tsukada,et al.  Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. , 2009, Nuclear medicine and biology.

[113]  W. Pardridge Brain Drug Targeting: The Future of Brain Drug Development , 2001 .

[114]  Xin-guo Jiang,et al.  The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats , 2006, Journal of drug targeting.

[115]  P. Gao,et al.  Tissue distribution of borneol-modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[116]  Lihong Liu,et al.  Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[117]  Jie Ren,et al.  Preparation and Therapeutic Efficacy of Polysorbate-80-Coated Amphotericin B/PLA-b-PEG Nanoparticles , 2009, Journal of biomaterials science. Polymer edition.

[118]  Bernhard A. Sabel,et al.  Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections , 1996, Brain Research.

[119]  R. Nerem,et al.  Effect of flow on the process of endothelial cell division. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[120]  Xing Tang,et al.  Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[121]  Iain Martin,et al.  Prediction of blood-brain barrier penetration: are we missing the point? , 2004, Drug discovery today.

[122]  J. Diamond,et al.  Molecular forces governing non-electrolyte permeation through cell membranes , 1969, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[123]  H. Galla,et al.  Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. , 2011, Biochemical and biophysical research communications.

[124]  A. Misra,et al.  Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting , 2008, Alzheimer disease and associated disorders.

[125]  Wenwei Tang,et al.  Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[126]  de Lange EC,et al.  Microdialysis for pharmacokinetic analysis of drug transport to the brain. , 1999, Advanced drug delivery reviews.

[127]  H. Berendsen,et al.  Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. , 1996, Biophysical journal.

[128]  C. Soussain,et al.  Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma , 2007, Clinical Cancer Research.

[129]  D. Mishra,et al.  Formulation, optimization, in vivo pharmacokinetic, behavioral and biochemical estimations of minocycline loaded chitosan nanoparticles for enhanced brain uptake. , 2013, Chemical & pharmaceutical bulletin.

[130]  J. Poirier,et al.  2 International Journal of Alzheimer ’ s Disease 2 . Structural Organization and Toxicological Properties of the APOE Protein 2 , 2011 .

[131]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[132]  S. Rapoport,et al.  Examination of Blood — Brain Barrier Permeability in Dementia of the Alzheimer Type with [68Ga]EDTA and Positron Emission Tomography , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[133]  Tushar K. Vyas,et al.  Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. , 2008, Journal of pharmaceutical sciences.

[134]  Mauro Ferrari,et al.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.

[135]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[136]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[137]  N. Zhang,et al.  Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. , 2008, International journal of pharmaceutics.

[138]  A. Reichel Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept , 2009, Chemistry & biodiversity.

[139]  Sandip S Chavhan,et al.  Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route , 2011, Journal of drug targeting.

[140]  S. Tzeng,et al.  Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. , 2008, Biomaterials.

[141]  Svetlana Gelperina,et al.  Transport of drugs across the blood-brain barrier by nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[142]  C F Dewey,et al.  The dynamic response of vascular endothelial cells to fluid shear stress. , 1981, Journal of biomechanical engineering.

[143]  T. Matsuda,et al.  Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[144]  A. Rawat,et al.  Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting.

[145]  J. Varshosaz,et al.  Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model , 2011, International journal of nanomedicine.

[146]  T. Maurer,et al.  RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.

[147]  M. Bynoe,et al.  Adenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier , 2011, The Journal of Neuroscience.

[148]  E. Duysen,et al.  Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. , 2010, Chemico-biological interactions.

[149]  A. Seelig,et al.  A method to determine the ability of drugs to diffuse through the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[150]  Lisbeth Illum,et al.  Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.

[151]  Siling Wang,et al.  Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting. , 2010, International journal of pharmaceutics.

[152]  Peter L. Bonate,et al.  Animal models for studying transport across the blood-brain barrier , 1995, Journal of Neuroscience Methods.

[153]  U. Sharma,et al.  The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. , 2012, Biomaterials.

[154]  P. Couvreur,et al.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles , 1992, Investigational New Drugs.

[155]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[156]  K. Audus,et al.  Characterization of an In Vitro Blood–Brain Barrier Model System for Studying Drug Transport and Metabolism , 1986, Pharmaceutical Research.

[157]  Rishi Kapil,et al.  Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery , 2011, The Journal of pharmacy and pharmacology.

[158]  Mehrdad Hamidi,et al.  Brain drug targeting: a computational approach for overcoming blood-brain barrier. , 2009, Drug discovery today.

[159]  Liang Jiang,et al.  Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model , 2009, Brain Research.

[160]  G. Curran,et al.  Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy , 2008, Pharmaceutical Research.

[161]  P. Couvreur,et al.  Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles , 2008, Cancer Chemotherapy and Pharmacology.

[162]  T. Aminabhavi,et al.  Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[163]  B A Sabel,et al.  Influence of Nanoparticles on the Brain‐to‐serum Distribution and the Metabolism of Valproic Acid in Mice , 2000, The Journal of pharmacy and pharmacology.

[164]  J. Kreuter,et al.  Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[165]  Janine Doorduin,et al.  Evaluation of [11C]-DAA1106 for imaging and quantification of neuroinflammation in a rat model of herpes encephalitis. , 2010, Nuclear medicine and biology.

[166]  W. Pardridge Why is the global CNS pharmaceutical market so under-penetrated? , 2002, Drug discovery today.

[167]  D. Luo,et al.  Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. , 2008, Biomaterials.

[168]  M. Castanho,et al.  In vitro blood-brain barrier models--latest advances and therapeutic applications in a chronological perspective. , 2010, Mini reviews in medicinal chemistry.

[169]  I. Fichtner,et al.  Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models , 2001, Pharmaceutical Research.

[170]  A. Misra,et al.  Improved transnasal transport and brain uptake of tizanidine HCl-loaded thiolated chitosan nanoparticles for alleviation of pain. , 2012, Journal of pharmaceutical sciences.

[171]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[172]  Mansoor M. Amiji,et al.  Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.

[173]  Denis Guilloteau,et al.  PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter , 2008, CNS neuroscience & therapeutics.

[174]  E. Guatteo,et al.  A dynamic model of the blood-brain barrier "in vitro". , 1996, Neurotoxicology.

[175]  W. Pardridge,et al.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.

[176]  Jin-Oh You,et al.  Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. , 2008, Biomaterials.

[177]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[178]  Stina Syvänen,et al.  On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.

[179]  W. Pardridge BBB-Genomics: creating new openings for brain-drug targeting. , 2001, Drug discovery today.

[180]  G. Tosi,et al.  Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[181]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[182]  S. Charman,et al.  Drug delivery: A key factor in realising the full therapeutic potential of drugs , 1999 .

[183]  Patrick Couvreur,et al.  Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. , 2005, Bioconjugate chemistry.

[184]  D. Mishra,et al.  Nanoparticle mediated brain targeted delivery of gallic acid: in vivo behavioral and biochemical studies for improved antioxidant and antidepressant-like activity , 2012, Drug delivery.

[185]  M. Ricci,et al.  Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.

[186]  R. Löbenberg,et al.  Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[187]  Thomas Wirth,et al.  Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[188]  Jia-You Fang,et al.  Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. , 2012, International journal of pharmaceutics.

[189]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[190]  P. Diwan,et al.  β-Hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[191]  T. Terasaki,et al.  Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: Involvement of a pyrilamine-sensitive organic cation transport process , 2013, Neurochemistry International.

[192]  William Couet,et al.  Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity , 1999, Pharmaceutical Research.

[193]  D. Begley,et al.  Brain Targeting Of Nerve Growth Factor Using Poly(Butylcyanoacrylate) Nanoparticles , 2004 .

[194]  Jim E Riviere,et al.  Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[195]  K. Frei,et al.  Molecular and cellular permeability control at the blood–brain barrier , 2001, Brain Research Reviews.

[196]  P. Dore‐Duffy,et al.  Role of the CNS microvascular pericyte in the blood‐brain barrier , 1998, Journal of neuroscience research.

[197]  L. Rubin,et al.  The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.

[198]  A. O. Kamel,et al.  Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route. , 2012, Colloids and surfaces. B, Biointerfaces.

[199]  Mansoor M Amiji,et al.  Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases , 2009, Expert opinion on drug delivery.

[200]  R. Weissleder,et al.  Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. , 1995, The American journal of pathology.

[201]  Sungho Jin,et al.  Magnetic targeting of nanoparticles across the intact blood-brain barrier. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[202]  Y. Cai,et al.  Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[203]  S. Apparsundaram,et al.  Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats , 2009, Drug Metabolism and Disposition.

[204]  Simon M. Lin,et al.  Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. , 2012, Drug discovery today.

[205]  Lei Zhang,et al.  Gum Arabic-Coated Magnetic Nanoparticles for Potential Application in Simultaneous Magnetic Targeting and Tumor Imaging , 2009, The AAPS Journal.

[206]  V. Narayanaswami,et al.  Apolipoprotein E: from lipid transport to neurobiology. , 2011, Progress in lipid research.

[207]  J. Kreuter,et al.  Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[208]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[209]  S. Desrayaud,et al.  The priorities/needs of the pharmaceutical industry in drug delivery to the brain , 2005 .

[210]  K. Knight,et al.  Intraarterial chemotherapy and osmotic blood‐brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system , 2008, Cancer.

[211]  Harpreet S. Chadha,et al.  Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. , 1995, Drug design and discovery.

[212]  J. Leysen,et al.  Partition coefficients of dopamine antagonists in brain membranes and liposomes. , 1989, Biochemical pharmacology.